Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?

Authors :: Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE)
Mocroft, Amanda
Reiss, Peter
Kirk, Ole
Mussini, Cristina
Girardi, Enrico
Morlat, Philippe
Stephan, Christoph
De Wit, Stéphane
Doerholt, Katja
Ghosn, Jade
Bucher, Heiner H.C.
Lundgren, Jens D
Chêne, Geneviève
Miró, José María
Furrer, Hansjakob
Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE)
Mocroft, Amanda
Reiss, Peter
Kirk, Ole
Mussini, Cristina
Girardi, Enrico
Morlat, Philippe
Stephan, Christoph
De Wit, Stéphane
Doerholt, Katja
Ghosn, Jade
Bucher, Heiner H.C.
Lundgren, Jens D
Chêne, Geneviève
Miró, José María
Furrer, Hansjakob
Source :: Clinical infectious diseases, 51 (5
Publication Year :: 2010
Abstract: Current guidelines suggest that primary prophylaxis for Pneumocystis jiroveci pneumonia (PcP) can be safely stopped in human immunodeficiency virus (HIV)-infected patients who are receiving combined antiretroviral therapy (cART) and who have a CD4 cell count >200 cells/microL. There are few data regarding the incidence of PcP or safety of stopping prophylaxis in virologically suppressed patients with CD4 cell counts of 101-200 cells/microL.<br />SCOPUS: ar.j<br />info:eu-repo/semantics/published

Tools